Key result
Ivabradine aids rate control in refractory neonatal congenital junctional ectopic tachycardia.
Why the study?
Congenital junctional ectopic tachycardia is a rare and serious arrhythmia in neonates and young infants that is often resistant to first-line treatments and associated with high morbidity and mortality.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Ivabradine may control refractory congenital JET in neonates; hypothesis-generating and should not yet change practice.
Congenital junctional ectopic tachycardia is a rare but serious cardiac arrhythmia seen in neonates and young infants. It is frequently resistant and refractory to first-line treatment options such as cardioversion with adenosine and direct current shock, and it carries a high morbidity and mortality rate. The aim of this article is to present the case of congenital junctional ectopic tachycardia observed in a 14-day-old neonate, highlighting the role of ivabradine in the management, followed by a discussion about current approaches to treatment.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted a case report in Congenital junctional ectopic tachycardia (n=1). Ivabradine was evaluated. Ivabradine played a highlighted role in the management of a 14-day-old neonate with refractory congenital junctional ectopic tachycardia.
Synapse has enriched 10 related papers. Consider them for comparative context: